Skip to main content

Table 6 HRs and 95% CIs of incident eGFR decline ≥ 40% according to tertiles of FPG variability measures in Multi-Ethnic Study of Atherosclerosis

From: The association between fasting plasma glucose variability and incident eGFR decline: evidence from two cohort studies

Variability measures

Model 1

Model 2

Model 3

Model 4

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

With diabetes

SD

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.48 (0.69–3.19)

1.28 (0.58–2.81)

1.26 (0.57–2.77)

1.18 (0.53–2.60)

 T3

2.15 (1.03–4.50)

1.38 (0.59–2.22)

1.96 (0.93–4.17)

1.46 (0.64–3.34)

 P trend

0.040

0.459

0.069

0.367

CV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.81 (0.37–1.79)

0.65 (0.29–1.49)

0.70 (0.31–1.57)

0.66 (0.29–1.49)

 T3

1.78 (0.91–3.47)

1.32 (0.65–2.70)

1.60 (0.81–3.16)

1.35 (0.67–2.75)

 P trend

0.073

0.326

0.128

0.307

ARV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.48(0.67–3.30)

1.16 (0.50–2.68)

1.35 (0.60–3.06)

1.20 (0.53–2.75)

 T3

2.45 (1.16–5.16)

1.79 (0.79–4.08)

2.31 (1.08–4.96)

1.78 (0.78–4.06)

 P trend

0.015

0.132

0.025

0.145

VIM

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.54 (0.24–1.23)

0.51 (0.22–1.18)

0.50 (0.21–1.13)

0.48 (0.21–1.12)

 T3

1.52 (0.80–2.87)

1.39 (0.72–2.69)

1.35 (0.70–2.61)

1.49 (0.76–2.93)

 P trend

0.155

0.234

0.264

0.178

Without diabetes

SD

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.57 (0.30–1.09)

0.59 (0.31–1.14)

0.59(0.31–1.13)

0.59 (0.30–1.13)

 T3

0.93 (0.53–1.64)

0.95 (0.53–1.68)

0.88 (0.49–1.56)

0.87 (0.49–1.55)

 P trend

0.744

0.804

0.623

0.603

CV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.74 (0.40–1.36)

0.79 (0.43–1.45)

0.76 (0.41–1.40)

0.76 (0.41–1.40)

 T3

0.82 (0.45–1.49)

0.86 (0.47–1.58)

0.80 (0.44–1.46)

0.80 (0.44–1.46)

 P trend

0.483

0.600

0.445

0.444

ARV

    

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.77 (0.42–1.39)

0.74 (0.41–1.35)

0.74 (0.41–1.35)

0.74 (0.41–1.34)

 T3

0.70 (0.38–1.30)

0.69 (0.37–1.28)

0.65 (0.35–1.21)

0.64 (0.34–1.19)

 P trend

0.243

0.215

0.160

0.148

VIM

    

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

0.67 (0.36–1.24)

0.73 (0.39–1.36)

0.70 (0.38–1.30)

0.70 (0.38–1.29)

 T3

0.78 (0.43–1.41)

0.83 (0.45–1.52)

0.77 (0.43–1.40)

0.77 (0.43–1.41)

 P trend

0.384

0.516

0.372

0.375

  1. Model 1: adjusted for age and sex at baseline (phase 2)
  2. Model 2: Model 1 + marital status, education, ever smoking, prevalent CVD, physical activity, anti-diabetic drug use, anti-hypertensive drug, lipid-lowering drug, BMI, WC, SBP, DBP, eGFR, and FPG at baseline (phase 2)
  3. Model 3: Model 1 + marital status, education, ever smoking, prevalent CVD, and physical activity at baseline (phase 2), and anti-diabetic drug use, anti-hypertensive drug, and lipid-lowering drug over phases 2–4, and average BMI, WC, SBP, DBP, and eGFR over phases 2–4
  4. Model 4: Model 3 + average FPG
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us